Global Companies May See Sharp Price Cuts As India Approves New Drug Pricing Policy
This article was originally published in PharmAsia News
A committee of Indian cabinet ministers has agreed to determine drug pricing on a simple average of products sold in a particular therapy area. The decision will lead to lower drug prices but the industry is set to face tougher market competition.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.